Arrhythmogenic right ventricular cardiomyopathy is a disease of cardiac stem cells

Current Opinion in Cardiology

Volumn 25, Issue 3, 2010, Pages 222-228

  Lombardi, Raffaella ^a,b   Marian, Ali J ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cardiomyopathy; Genetics; Heart failure; Stem cells; Sudden death

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESMOCOLLIN; DESMOGLEIN 2; DESMOPLAKIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLAKOGLOBIN; PLAKOPHILIN; SOTALOL; TRANSFORMING GROWTH FACTOR BETA1; WNT PROTEIN;

ADIPOCYTE; CARDIAC STEM CELL; CATHETER ABLATION; CELL DIFFERENTIATION; DESMOSOME; DRUG TARGETING; GENE MUTATION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; MOLECULAR GENETICS; MUSCLE CELL; MYOCARDIAL DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ADIPOCYTES; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CELL DIFFERENTIATION; DESMOSOMES; HEART VENTRICLES; HUMANS; MOLECULAR BIOLOGY; MUTATION; MYOCARDIUM; STEM CELLS;

EID: 77952134035     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283376daf     Document Type: Review

References (44)

1. Frank R, Fontaine G, Vedel J, et al. Electrocardiology of 4 cases of right ventricular dysplasia inducing arrhythmia. Archives Des Maladies Du Coeur Et Des Vaisseaux 1978;71:963-972.
2. Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation 2000; 101: E101-E106.
3. Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005;112:636-642.
4. Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 2002;40:1445-1450.
5. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988;318:129-133.
6. Corrado D, Thiene G, Nava A, et al. Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med 1990;89:588-596.
7. Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003;108:3000-3005.
8. Shen WK, Edwards WD, Hammill SC, et al. Sudden unexpected nontraumatic death in 54 young adults: a 30-year population-based study. Am J Cardiol 1995;76:148-152.
9. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. J Am Med Assoc 1996;276:199-204.
10. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007;115:1710-1720.
11. Lombardi R, Dong J, Rodriguez G, et al. Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res 2009;104:1076-1084. The findings delineate the cellular origin of adipocytes in arrhythmogenic right ventricular cardiomyopathy (ARVC), which has been an enigma since the initial description of the phenotype more than two decades ago. The authors show that nuclear localization of plakoglobin, a desmosomal protein, suppresses the canonical Wnt signaling and leads to differentiation of a subset of second heart field progenitor cells to adipocytes. The investigators further collaborate their findings in human heart samples from patients with ARVC.
12. Steriotis AK, Bauce B, Daliento L, et al. Electrocardiographic pattern in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2009;103:1302-1308.
13. Piccini JP, Nasir K, Bomma C, et al. Electrocardiographic findings overtime in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol 2005;96:122-126.
14. Auffermann W, Wichter T, Breithardt G, et al. Arrhythmogenic right ventricular disease: MR imaging vs. angiography. AJR Am J Roentgenol 1993;161:549-555.
15. Tandri H, Castillo E, Ferrari VA, et al. Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia: sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle. J Am Coll Cardiol 2006;48:2277-2284.
16. Marcus FI, Zareba W, Calkins H, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm 2009;6:984-992.
17. Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2009;360:1075-1084. The authors describe reduced plakoglobin at cardiac myocyte junctions, detected by immunofluorescence staining, as a diagnostic marker for ARVC.
18. Tandri H, Asimaki A, Abraham T, et al. Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2009;6:769-775.
19. Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation 1998;97:1571-1580.
20. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003;99:1-19.
21. Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001;10:189-194.
22. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200. (Pubitemid 32095402)
23. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000;355:2119-2124.
24. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004;36:1162-1164.
25. Heuser A, Plovie ER, Ellinor PT, et al. Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2006;79:1081-1088.
26. Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 2000;9:2761-2766.
27. Alcalai R, Metzger S, Rosenheck S, et al. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J Am Coll Cardiol 2003;42:319-327.
28. van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2006;113:1650-1658.
29. Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113:1171-1179.
30. Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet 2006;79:978-984.
31. Beffagna G, De Bortoli M, Nava A, et al. Missense mutations in desmocollin-2 N-terminus, associated with arrhythmogenic right ventricular cardiomyopathy, affect intracellular localization of desmocollin-2 in vitro. BMC Med Genet 2007;8:65.
32. Beffagna G, Occhi G, Nava A, et al. Regulatory mutations in transforming growth factorbeta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 2005;65:366-373.
33. Merner ND, Hodgkinson KA, Haywood AFM, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 2008;82:809-821.
34. Garcia-Gras E, Lombardi R, Giocondo MJ, et al. Suppression of canonical Wnt/betacatenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006;116:2012-2021.
35. Maeda O, Usami N, Kondo M, et al. Plakoglobin (gamma-catenin) has TCF/LEF family dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 2004;23:964-972.
36. Klymkowsky MW, Williams BO, Barish GD, et al. Membrane-anchored plakoglobins have multiple mechanisms of action in Wnt signaling. Mol Biol Cell 1999;10:3151-3169.
37. Zhurinsky J, Shtutman M, Ben Ze'ev A. Differential mechanisms of LEF/TCF family dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol 2000;20:4238-4252.
38. Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling. Science 2000;289:950-953.
39. Polesskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45+Adult stem cells during muscle regeneration. Cell 2003;113:841-852.
40. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 2005;433:317-322.
41. Ai D, Fu X, Wang J, et al. Canonical Wnt signaling functions in second heart field to promote right ventricular growth. Proc Natl Acad Sci U S A 2007;104:9319-9324.
42. Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol 2009;54:609-615.
43. Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;86:29-37.
44. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108:3084-3091.